|
|
|
|
| LEADER |
04333nma a2201237 u 4500 |
| 001 |
EB001967066 |
| 003 |
EBX01000000000000001129968 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a books978-3-03921-314-6
|
| 020 |
|
|
|a 9783039213139
|
| 020 |
|
|
|a 9783039213146
|
| 100 |
1 |
|
|a Reischl, Gerald
|
| 245 |
0 |
0 |
|a Targets, Tracers and Translation - Novel Radiopharmaceuticals Boost Nuclear Medicine
|h Elektronische Ressource
|
| 260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2019
|
| 300 |
|
|
|a 1 electronic resource (214 p.)
|
| 653 |
|
|
|a MMPEP
|
| 653 |
|
|
|a microglia
|
| 653 |
|
|
|a apparent molar activity
|
| 653 |
|
|
|a ceftriaxone
|
| 653 |
|
|
|a technetium-99m
|
| 653 |
|
|
|a hypoxia
|
| 653 |
|
|
|a 177Lu-radiopharmaceuticals
|
| 653 |
|
|
|a [18F]FMISO
|
| 653 |
|
|
|a PET
|
| 653 |
|
|
|a positron emission tomography
|
| 653 |
|
|
|a benzotriazine-1
|
| 653 |
|
|
|a phosphoramidon
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a NPY(Y1)R
|
| 653 |
|
|
|a rituximab
|
| 653 |
|
|
|a ?-CIT.
|
| 653 |
|
|
|a pretargeting
|
| 653 |
|
|
|a gastrin-releasing peptide receptor
|
| 653 |
|
|
|a SR 4317
|
| 653 |
|
|
|a girentuximab
|
| 653 |
|
|
|a PET/CT imaging
|
| 653 |
|
|
|a small animal imaging
|
| 653 |
|
|
|a ketamine
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a PSMA-617
|
| 653 |
|
|
|a gallium-68
|
| 653 |
|
|
|a electrophilic radioiodination
|
| 653 |
|
|
|a sentinel lymph node
|
| 653 |
|
|
|a hydrazinonicotinic acid (HYNIC)
|
| 653 |
|
|
|a Iodo-Gen®
|
| 653 |
|
|
|a [18F]PSS232
|
| 653 |
|
|
|a tirapazamine (TPZ)
|
| 653 |
|
|
|a cholecystokinin-2 receptor
|
| 653 |
|
|
|a 99mTc-radioligand
|
| 653 |
|
|
|a oncogenic fusions
|
| 653 |
|
|
|a neurodegeneration
|
| 653 |
|
|
|a salivary gland uptake
|
| 653 |
|
|
|a endoradiotherapy
|
| 653 |
|
|
|a tumor hypoxia
|
| 653 |
|
|
|a click chemistry
|
| 653 |
|
|
|a carbon-11
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a neuroinflammation
|
| 653 |
|
|
|a separation
|
| 653 |
|
|
|a breast cancer
|
| 653 |
|
|
|a azomycin nucleosides
|
| 653 |
|
|
|a Fusarinine C
|
| 653 |
|
|
|a glutamate
|
| 653 |
|
|
|a peptide heterodimers
|
| 653 |
|
|
|a benzotriazine-1-monoxide (BTMO)
|
| 653 |
|
|
|a radioiodination
|
| 653 |
|
|
|a minigastrin
|
| 653 |
|
|
|a bombesin
|
| 653 |
|
|
|a radiosynthesis
|
| 653 |
|
|
|a ABP688
|
| 653 |
|
|
|a radiochemistry
|
| 653 |
|
|
|a dextran
|
| 653 |
|
|
|a molecular imaging
|
| 653 |
|
|
|a iodine-131
|
| 653 |
|
|
|a Chloramine T
|
| 653 |
|
|
|a radiometals
|
| 653 |
|
|
|a [11C]meta-hydroxyephedrine
|
| 653 |
|
|
|a tumor targeting
|
| 653 |
|
|
|a 68Ga
|
| 653 |
|
|
|a mannose
|
| 653 |
|
|
|a carbonic anhydrase IX
|
| 653 |
|
|
|a metabotropic glutamate receptor subtype 5
|
| 653 |
|
|
|a gastrin-releasing peptide
|
| 653 |
|
|
|a 99mTc-radiopharmaceuticals
|
| 653 |
|
|
|a metabolic stability
|
| 653 |
|
|
|a GRPR
|
| 653 |
|
|
|a radiosensitizer
|
| 653 |
|
|
|a 4-dioxide (BTDO)
|
| 653 |
|
|
|a radioimmunotherapy
|
| 653 |
|
|
|a tropomyosin receptor kinase
|
| 653 |
|
|
|a multimerization
|
| 653 |
|
|
|a oxidizing agent
|
| 653 |
|
|
|a allosteric modulator
|
| 653 |
|
|
|a neprilysin-inhibition
|
| 653 |
|
|
|a renal cell carcinomas
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-03921-314-6
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/60492
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/1555
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 540
|
| 520 |
|
|
|a This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences.
|